REG - Physiomics PLC - General Meeting Request

PhysiomicsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260316:nRSP7510Wa&default-theme=true

RNS Number : 7510W  Physiomics PLC  16 March 2026

16 March 2026

 

Physiomics plc

 

("Physiomics" or the "Company")

 

General Meeting Request

 

The directors of Physiomics plc (AIM: PYC) announce that at 2114h on 13 March
2026 they received a request submitted pursuant to section 303 of the
Companies Act 2006 (the "Act") requiring the Board to convene a general
meeting of the Company's shareholders (the "GM Request"). The GM Request was
accompanied by a shareholder statement submitted pursuant to section 314 of
the Act.

 

The GM Request has been submitted by Michael Whitlow, who the Board
understands holds approximately 13.68% of the Company's issued ordinary share
capital. The resolutions proposed in the GM Request comprise four separate
resolutions which, if all passed, would have the immediate effect of
appointing Nicholas Tulloch, Michael Whitlow, Ian Bagnall, and Martin
Gouldstone as directors of the Company (the "Appointment Resolutions"). In
addition, four further resolutions propose the removal of Dr Jim Millen,
Shalabh Kumar, Dr Tim Corn, and Dr Peter Sargent as directors, each of which
is conditional on at least two of the aforementioned Appointment Resolutions
being passed. If all Appointment Resolutions are passed, and subsequently all
of the removal resolutions are passed, this would result in the full
replacement of the entire existing Board.

 

The Board is currently taking legal advice to confirm that the Request
complies with the formal requirements of section 303 of the Act.

 

Subject to validation of the GM Request, and in accordance with section 304 of
the Act, the Board will be required to give notice of a general meeting within
21 days of receipt of the Request (i.e., by no later than 3 April 2026). It
is noted that the requisitioned general meeting notice, if valid, must be held
on a date not more than 28 days after the date of the notice convening it, and
in such circumstances the Company would circulate Mr Whitlow's section 314
statement together with the notice of the general meeting requested, as
required by the Act.

 

It is noted that the directors had been approached by Mr Whitlow and were in
dialogue with him at the time the GM Request was received. The directors are
considering the GM Request carefully, however are united in their view that
the wholesale replacement of the current Board would be highly detrimental to
the Company and its shareholders. A further announcement will be made in due
course.

 

 

For further information, please contact:

 Physiomics plc                    +44 (0) 1235 841575
 Dr Peter Sargent, CEO

 Hybridan LLP (Broker)             +44 (0) 203 764 2341
 Claire Louise Noyce

 Strand Hanson Limited (NOMAD)     +44 (0) 20 7409 3494

 James Dance & James Bellman

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of
the European Union (Withdrawal) Act 2018 (as amended).

Further information on the Company can be found on its website at
www.physiomics.co.uk

 

The Company's LEI is 213800A71DSZ6ABMTQ91.

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep
biology expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all
relevant and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and clinical
studies. Through use of cutting-edge computational
tools, bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 140 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics &
CRUK.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGZGMFMKRGVZZ



            Copyright 2019 Regulatory News Service, all rights reserved